Company / Current Assets
Amylyx Pharmaceuticals, Inc. Current Assets History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$323.7M
FY2025
5-year range
$105.0M / $464.7M
FY2021-FY2025
Trend
+70.9%
vs FY2024
Sector context
#155 of 213
Health Care
What the data says
At $324M, Amylyx Pharmaceuticals, Inc.'s current assets ranks #155 of 213 in the Health Care sector. Declined from $465M to $324M over the past 2 years.
Based on SEC 10-K filings.
$324M in FY2025 with a 3-year CAGR of -5.4%.
Declined from $465M to $324M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- -5.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#155 of 213 in Health CareTop 73% of 213This company $323.7M Sector average $2.5B
▼
-87.2% below sector average
Key checks
Key Insights
- 3-year CAGR of -5.4%, indicating a declining trend.
- In FY2025, current assets increased 70.9% year-over-year.
- Ranks #155 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $323.7M | +70.9% |
| FY2024 | $189.4M | -59.2% |
| FY2023 | $464.7M | +21.6% |
| FY2022 | $382.1M | +264.1% |
| FY2021 | $105.0M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026